Utilising Circulating Tumour DNA (ctDNA) to optimise the adjuvant therapy and follow-up of patients with locally advanced rectal cancer

利用循环肿瘤DNA（ctDNA）优化局部晚期直肠癌患者的辅助治疗和随访

• 批准号: nhmrc : 1124377
• 负责人: Prof Bert Vogelstein
• 金额: $ 90.08万
• 依托单位: The Walter and Eliza Hall Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/utilising-circulating-tumour-rectal-cancer/947335
• 关键词: Utilising; Circulating; Tumour; DNA; ctDNA

The management of patients after surgery for rectal cancer presents multilpe dilemmas; what treatment should be given and to which patients? Our initial studies in colorectal cancer patients demonstrate that a novel blood biomarker (circulating tumour DNA) can accurately predict patient risk of recurrence and with serial samples, can indicate whether chemotherapy is being effective. During follow-up changes in this biomarker promise to be a specific and very early indicator of cancer recurrence.

直肠癌术后患者的管理面临多重困境；应该给哪些病人什么样的治疗？我们在结直肠癌患者中的初步研究表明，一种新的血液生物标志物（循环肿瘤DNA）可以准确预测患者复发的风险，并且通过系列样本可以表明化疗是否有效。在随访期间，这种生物标志物的变化有望成为癌症复发的特异性和非常早期的指标。